1. Introduction {#sec1}
===============

The emergence and spread of community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) are serious public health problems worldwide. In contrast to healthcare-associated MRSA (HA-MRSA) infections, for which there is a predisposing risk factor or condition, CA-MRSA infections can occur in healthy individuals, suggesting that CA-MRSA strains have enhanced virulence compared with traditional HA-MRSA strains ([@bib7]). *S. aureus* is a prevalent human pathogen that causes numerous infectious diseases from mild skin and soft-tissue infections to severe systemic infections such as sepsis and necrotizing pneumonia ([@bib6]; [@bib7]).

The resistance of MRSA to β-lactam antibiotics is associated with penicillin-binding protein 2′ encoded by the *mecA* gene, which is located on a mobile genetic element called staphylococcal cassette chromosome *mec* (SCC*mec*) ([@bib21]). In addition to *mecA*, the SCC*mec* region contains site-specific cassette chromosome recombinases (*ccr*) that are responsible for the integration of SCC*mec* into the *S. aureus* genome. In general, SCC*mec* types have been reported to differ between CA-MRSA and HA-MRSA. SCC*mec* types I, II, and III are common in HA-MRSA, whereas CA-MRSA harbors SCC*mec* types IV, V, VI, VII, and VIII ([@bib12]; [@bib6]). Additionally, some reports have demonstrated that SCC*mec* type IV strains are susceptible to imipenem and cefazolin ([@bib17]; [@bib25]).

An important cytotoxin produced by *S. aureus* is Panton-Valentine leukocidin (PVL), which is encoded by two genes, *lukS*-PV and *lukF*-PV ([@bib3]). In Europe and the USA, PVL is harbored by the majority of CA-MRSA strains and is rarely present in hospital isolates. Therefore, PVL is recognized as a marker of CA-MRSA ([@bib7]). PVL gene-positive CA-MRSA strains cause severe suppurative infections such as skin abscess formation, pleural effusion, and necrotizing pneumonia ([@bib4]; [@bib6]). The most abundant CA-MRSA strains in Europe were reported to be distinct from those in North America, Oceania, and other parts of the world ([@bib20]), and the PVL-positive rate in CA-MRSA strains varies by country and area ([@bib6]). The rate of PVL gene-positive CA-MRSA in Japan was reported to be low compared with Western countries, and CA-MRSA strains isolated in Japan were reported to be genetically diverse ([@bib25]; [@bib26]). Therefore, comparing the molecular epidemiology of strains with that of strains from other countries provides comprehensive information about the spread of CA-MRSA. In this study, we analyzed the SCC*mec* structure of PVL gene-positive CA-MRSA strains isolated from outpatients at Showa University Hospital between September 2009 and March 2017.

2. Materials and methods {#sec2}
========================

2.1. Bacterial isolates and antimicrobial susceptibility tests {#sec2.1}
--------------------------------------------------------------

MRSA strains from 1107 samples (blood, sputum, skin, wound, bile, and pharynx) from outpatients were collected at Showa University Hospital in Japan between September 2009 and March 2017. The hospital is located in the Southern part of Tokyo. It has 1000 beds and an average of 44,500 to 53,000 outpatients per month.

Identification and antimicrobial susceptibility tests were performed by Microscan WalkAway using the Pos Comb 3.1J panel (Siemens Healthcare Diagnostics. Deerfield, IL). Susceptibility intermediate and resistant (SIR) categories of penicillin G, oxacillin, ampicillin, cefazolin, cefotiam, imipenem, gentamicin, erythromycin, clindamycin, minocycline, vancomycin, levofloxacin, teicoplanin, and linezolid were classified according to the Clinical Laboratory Standards Institute guidelines ([@bib5]).

2.2. DNA extraction and PCR {#sec2.2}
---------------------------

Bacterial DNA was extracted using Sepagene (EIDIA Co. Ltd. Tokyo, Japan) and 10 ng was used as the template for PCR. The PCR assays were performed in a 25 μl mixture containing 1.5 mM MgCl~2~, 1 mM dNTP, 1 unit Roche taq polymerase, and each forward and reverse primer listed in [Table 1](#tbl1){ref-type="table"} at a concentration of 2 mM ([@bib2]; [@bib10]; [@bib13]; [@bib14]; [@bib28]). PCR cycling comprised 30 sec at 95 °C, 30 sec at 60 °C, and 60 sec at 72 °C for 30 cycles, followed by a final elongation at 72 °C for 5 min using ABI9700 ([@bib9]).Table 1PCR primers used in this study.Table 1GeneNucleotide sequenceSize (bp)RefSCC*mec* type IF: GCTTTAAAGAGTGTCGTTACAGG\
R: GTTCTCTCATAGTATGACGTCC613[@bib28]SCC*mec* type IIF: CGTTGAAGATGATGAAGCG\
R: CGAAATCAATGGTTAATGGACC398[@bib28]SCC*mec* type IIIF: CCATATTGTGTACGATGCG\
R: CCTTAGTTGTCGTAACAGATCG280[@bib28]SCC*mec* type IvaF: GCCTTATTCGAAGAAACCG\
R: CTACTCTCTGAAAAGCGTCG776[@bib28]SCC*mec* type IVbF: TCTGGAATTACTTCAGCTGC\
R: AAACAATATTGCTCTCCCTC493[@bib28]SCC*mec* type IVcF: ACAATATTTGTATTATCGGAGAGC\
R: TTGGTATGAGGTATTGCTGG200[@bib28]SCC*mec* type IVdF: CTCAAAATACGGACCCCAATACA\
R: TGCTCCAGTAATTGCTAAAG881[@bib28]SCC*mec* type IVgF: GCAAGCTGTTATCGGCATTT\
R: GATCGTTCGTGTTTGTGTGC378[@bib28]SCC*mec* type IVhF: TTCCTCGTTTTTTCTGAACG\
R: CAAACACTGATATTGTGTCG664[@bib28]SCC*mec* type IViCB18F1: CCAAGAAATTAATGTCGTCG\
CB18R3: AGGCTTCAACGATTTGAGAAC1099This studySCC*mec* type IVjC18F1: ATCTGTTGACTTTGTCAACC\
C18R2: CGCTCTTAATTGAATTCTTCC331This studySCC*mec* type VF: GAACATTGTTACTTAAATGAGCG\
R: TGAAAGTTGTACCCTTGACACC325[@bib28]SCC*mec* type VIIF: CAGAGGCTCATCTACATCCT\
R: TGTTCTGCTATACCTTCCACA304[@bib10]*mecA*F: GTGAAGATATACCAAGTGATT\
R: ATGCGCTATAGATTGAAAGGAT147[@bib28]Class AF: CCCTTTTTATACAATCTCGTT\
R: ATATCATCTGCAGAATGGG146[@bib28]Class BF: TATTTTTGGGTTTCACTCGG\
R: CTCCACGTTAATTCCATTAATACC1305[@bib28]Class C1IS431F: ACATTAGATATTTGGTTGCGT\
*mec*RIR1: GTCTCCACGTTAATTCCATT239[@bib13]Class C2IS431R1(F):TGAGGTTATTCAGATATTTCGATGT\
*mec*AR1(R): TATACCAAACCCGACAAC832[@bib13]*ccr1ccr*AB-α2F: AACCTATATCATCAATCAGTACGT\
*ccr*ABβ2TR: ATTGCCTTGATAATAGCCTTCT\
*ccr*ABβ2CR: ATTGCCTTGATAATAGCCCTCT695[@bib28]*ccr2ccr*ABα3F: TAAAGGCATCAATGCACAAACACT\
*ccr*ABβ2TR: ATTGCCTTGATAATAGCCTTCT\
*ccr*ABβ2CR: ATTGCCTTGATAATAGCCCTCT937[@bib28]*ccr3ccr*ABα4F: AGCTCAAAAGCAAGCAATAGAAT\
*ccr*ABβ2TR: ATTGCCTTGATAATAGCCTTCT\
*ccr*ABβ2CR: ATTGCCTTGATAATAGCCCTCT1791[@bib28]*ccr4ccr*A4B4F: GTATCAATGCACCAGAACTT\
*ccr*A4B4R: TTGCGACTCTCTTGACGTTT1287[@bib14]*ccr5ccr*CF: ATGAATTCAAAGAGCATGGC\
*ccr*CR: GATTTAGAATTGTCGTGATTGC336[@bib28]

2.3. SCC*mec* typing {#sec2.3}
--------------------

The type of SCC*mec* was determined by a combination of the SCC*mec*-specific region, the type of *ccr* gene, and the class of *mec* gene complex, which is composed of *mecA*, *mecR1*, and *mecI*. Seven SCC*mec* Types, I, II, III, IV, V, VI, and VII; five *ccr* genes, *ccr1*, *ccr2, ccr3, ccr4, and ccr5*; and four class complexes, A, B, C1, and C2 were examined by PCR.

2.4. Ethics statement {#sec2.4}
---------------------

This study was approved by the research ethics committee of Showa University School of Health Sciences (Approval No. 371).

3. Results {#sec3}
==========

3.1. Isolation of CA-MRSA {#sec3.1}
-------------------------

CA-MRSA was identified in 342 strains from 342 patients classified as sensitive to cefazolin ≤8 μg/ml and imipenem ≤4 μg/ml among 1107 outpatient samples.

The PVL gene was detected in 46 of the 342 strains. Among 46 strains, 40 strains were isolated from severe suppurative lesions. The MIC values of the 46 strains are shown in [Supplementary Table 1](#appsec1){ref-type="sec"}. All MRSA isolates were susceptible to vancomycin, teicoplanin, linezolid, minocycline, and arbekacin, but some isolates were resistant to gentamicin (9/46 = 19.5%), erythromycin (38/46 = 82.6%), clindamycin (16/46 = 34.7%), and levofloxacin (21/46 = 45.6%).

3.2. SCC*mec* type {#sec3.2}
------------------

The results of PCR are summarized in [Table 2](#tbl2){ref-type="table"}. We determined the SCC*mec* type in the strains from two or three PCR products using the specific region, *ccr* type, and class type following the report by Zhang ([@bib28]). The SCC*mec* type, and corresponding *ccr* and class types are shown in [Supplementary Table 2](#appsec1){ref-type="sec"} ([@bib12]).Table 2Identified SCC*mec* type, and detection of the specific region, *ccr* type, and class type.Table 2SCC*mec* typeSubtypeSpecific regionClass type*ccr* typeNumber of Strains[∗](#tbl2fnlowast){ref-type="table-fn"}IVIVaIVaB215 (No. 2, 7, 8, 10, 12, 14, 15, 18, 22, 23, 27, 29, 34, 35, 41)IVaIVaBND8 (No. 24, 25, 31, 32, 37, 39, 40, 44)IVcIVcB23 (No.19, 20, 36)IVgIVgB21 (No. 16)IVhIVhB21 (No. 45)IV~NT~NDB25 (No. 9, 26, 33, 43, 46)VVC253 (No. 28, 38, 42)V+(III)C251 (No. 21)V+(III)ND51 (No. 11)VIIVII+(III)ND54 (No.3, 4, 13, 17)Unclassified(III)ND54 (No.1, 5, 6, 30)46[^1][^2][^3][^4]

Thirty-three strains were classified as SCC*mec* type IV (71.7%), and the SCC*mec* type IVa-specific region was identified in 23 strains. Of these 23 strains, class B was detected in all strains and *ccr2* was detected in 15 strains, but no *ccr* was found in the remaining 8 strains. Three strains were identified as SCC*mec* type IVc. One strain each was identified as SCC*mec* type IVg and IVh. For the remaining 5 strains, although class B and *ccr2* were positive, none of the SCC*mec* types, IVa, b, c, d, g, h, i, or j, were detected; therefore, they were categorized as IV~NT~ in this study. The SCC*mec* type V-specific region was detected in 5 strains (10.9%). *ccr5* was detected in all 5 strains and class C2 was detected in 4 of the 5 strains, but the class complex was not determined in 1 strain. Four strains were classified as SCC*mec* type VII because of possession of the VII-specific region and *ccr5*, although the class complex was not determined. For the remaining 4 strains, *ccr5* and the SCC*mec* type III-specific region, CZ049, were detected; therefore, they were considered to be an unclassified type. CZ049 was also detected in 2 type V strains and all 4 type VII strains.

4. Discussion {#sec4}
=============

Of the MRSA strains isolated from 1107 outpatient samples, 342 strains were identified as CA-MRSA. The PVL gene was detected in 48 strains (13.4%) of CA-MRSA. SCC*mec* analysis revealed that 33 strains (71.7%) were SCC*mec* type IV, 5 strains (10.9%) were type V, 4 strains (8.7%) were type VII, and 4 strains (8.7%) were an unclassified type. Among the 13 type V or VII strains, the SCC*mec* type III-specific region, CZ049, was detected in 10 strains.

The PVL-positive rate in CA-MRSA strains reported in Japan was low, being 2.3% (4/171) in 2008--2009 ([@bib27]) and 16.6% (3/18) in 2013 ([@bib15]), whereas is was high in other countries such as Colombia (92% in 2006--2007) ([@bib18]), India (48% in 2013) ([@bib22]), and Saudi Arabia (76% in 2016) ([@bib8]). The PVL-positive rate in the present study was 13.4% (46/342), which was lower than that in other countries.

The PVL gene has been epidemiologically linked to prevalent CA-MRSA strains harboring SCC*mec* type IV, V, VI, VII, and VIII ([@bib12]; [@bib6]). SCC*mec* type IV is associated with the major CA-MRSA strains, including USA type 300 and European clone ST80 ([@bib6]; [@bib19]), and has been reported in Japan ([@bib27]). SCC*mec* type V is rare in Europe and the USA, but SCC*mec* type V is detected more frequently than SCC*mec* type IV in Taiwan ([@bib23]) and Uganda ([@bib1]). In the present study, the prevalence of SCC*mec* types IV, V, and VII was 71.7%, 10.9%, and 8.7%, respectively, indicating that the routes of spreading of PVL-positive MRSA were diverse.

Among the SCC*mec* type IV subtypes, type IVa has been reported as the most common type. Type IVc has been frequently found in European MRSA isolates ([@bib2]). Type IVb has been found in USA but rarely in Japan ([@bib2]). In Japan, frequent isolation of types IVc and IVd was reported in the early 1980s (IVa 1/52 = 1%, IVc 37/52 = 38.1%, IVd 10/52 = 10.3%, IVn 4/52 = 4.1%) ([@bib16]). In the present study, IVc, IVg, and IVh, and 5 IV~NT~ strains were detected other than IVa. These 5 IV~NT~ strains may have novel SCC*mec* type and class complex structures.

Detection of the type III-specific region, CZ049 ([@bib28]), in 2 SCC*mec* type V strains ([@bib11]), 4 SCC*mec* type VII strains, and 4 unclassified strains may reflect recombination.

The positive rate of the PVL gene in CA-MRSA was lower at our hospital than that in other countries. Although the most prevalent PVL-positive CA-MRSA strains were SCC*mec* type IV with varying structures, the involvement of several SCC*mec* types was demonstrated.
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The following are the supplementary data related to this article:Supplementary Table 1Supplementary Table 1Supplementary Table 2Supplementary Table 2

[^1]: (III): products by type III-specific primers.

[^2]: ND: not determined.

[^3]: IV~NT~: non-typeable.

[^4]: Numbers in parenthesis correspond to [Supplementary Table 1](#appsec1){ref-type="sec"}.
